Biomaterial Database

A DNA vaccine targeting VEE virus delivered by needle-free jet-injection protects macaques against aerosol challenge. 2022

John J Suschak, and Sandra L Bixler, and Catherine V Badger, and Kristin W Spik, and Steven A Kwilas, and Franco D Rossi, and Nancy Twenhafel, and Melissa L Adams, and Charles J Shoemaker, and Erin Spiegel, and Jay W Hooper

U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter St, Fort Detrick, MD, 21702, USA.

We have previously shown that DNA vaccines expressing codon optimized alphavirus envelope glycoprotein genes protect both mice and nonhuman primates from viral challenge when delivered by particle-mediated epidermal delivery (PMED) or intramuscular (IM) electroporation (EP). Another technology with fewer logistical drawbacks is disposable syringe jet injection (DSJI) devices developed by PharmaJet, Inc. These needle-free jet injection systems are spring-powered and capable of delivering vaccines either IM or into the dermis (ID). Here, we evaluated the immunogenicity of our Venezuelan equine encephalitis virus (VEEV) DNA vaccine delivered by either the IM- or ID-DSJI devices in nonhuman primates. The protective efficacy was assessed following aerosol challenge. We found that a prime and single boost by either the IM or ID route resulted in humoral and cellular immune responses that provided significant protection against disease and viremia. Although the ID route utilized one-fifth the DNA dose used in the IM route of vaccination, and the measured humoral and cellular immune responses trended lower, the level of protection was high and performed as well as the IM route for several clinical endpoints.